The design and development of small molecule fluorescent ligands as imaging probes for neurological targets have been under intense investigation in recent years. This review will focus on recent advances in the design of small molecule fluorescent ligands and sophisticated imaging techniques utilised to effectively visualize these target molecules.
] This review will focus on some of these applications but is not intended to give an exhaustive list of all fluorescent ligands developed for CNS imaging assays, but rather to focus on selected examples in literature highlighting advances and potential application(s) of this methodology.
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emitted photon to have a lower energy and thus longer wavelength than that of the excited state. [ 3 ' 251 Singlet and triplet states refer to the energy level of a chromophore. Absorption of a photon causes a transition to an excited singlet state that decays to a corresponding triplet state. When an excited fluorophore is raised to a singlet state, it decays back to ground state in a variety of ways. negatively affected if the fluorophores are subject to these quenching mechanismsP 6 -281 Therefore, careful choice of the fluorophore that will be conjugated to the biological ligand and an understanding of the spectral properties of the molecule and imaging techniques to be used are of the utmost importance.
As a general rule, a fluorescent molecule excited at a given wavelength emits light at a longer wavelength. This phenomenon is described as the red or Stokes shift and allows the user to detect the emitted light over the background of the light source used to excite the fluorophore. [ 3 ' 261 In contrast, absorption spectrophotometry requires measurements of transmitted light relative to high indent light levels at the same wavelength. Stokes shift is often referred to in the literature when describing the fluorescence properties of a molecule. [ 23 
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Figure 1: The Jablonski diagram illustrating the processes involved for emission of fluorescence. At room temperature, molecules are predominantly present in the lowest vibrational level of the electronic ground state, S 0 • By absorbing light (energy) of the correct specific wavelength, a molecule can be excited (1) to any of the vibrational levels of the first excited electronic state SJ. The excited fluorophore will then lose energy and relax to the lowest vibrational level (2) of the excited state S J, from which it returns to any of the vibrational levels (3) of the ground state So thereby emitting a photon (fluorescence). [23J
Choice of Fluorescent labels (Fluorophores)
The design of a small molecule fluorescent ligand for CNS imaging starts from the selection ofthe appropriate fluorophore to be conjugated with the biologically active ligand. The basic criteria for selecting an appropriate fluorophore are: (i) It may not hinder binding by the ligand to the active site of the target-protein, i.e., the specificity and selectivity of the ligand to only one receptor or enzyme; (ii) It must be detectable in the visible spectrum and; (iii) It
should not affect the biological activity of the ligand. [ These molecules generally exhibit low quantum yield in aqueous solution but become highly fluorescent in nonpolar solvents or when bound to a hydrophobic site in proteins or membranes. [ 33 ' 35 ' 36 ] Another aspect to consider in the design of effective CNS fluorescent ligands, especially those to be used in in vivo imaging protocols, such as prodromal diagnostic tools for neurological disorders, is the ability of the ligand to permeate the blood-brain barrier (BBB 
Fluorescent ligands as imaging probes for CNS targets
Various CNS targets exist for the development of drugs as therapeutic agents against neurological disorders. This has presented researchers with the opportunity to design imaging technologies to aid in the drug design and discovery process by optimizing the process Despite a tripling of molecular weight compared to the parent agonist, all of the molecules displayed potent competitive agonism at the A1 receptor. One of these agonists, 1, was effectively used to visualize, by CLSM, the A1 receptor on CHO cells.
In addition to this study another group also reported a potential fluorescent ligand, The serotonin receptor (5-HT) has been implicated in a number of pathological disorders including; irritable bowel syndrome, gastroparesis, urinary incontinence, cardiac atrial arrhythmia and learning.
[ Consequently, serotonin receptors constitute a valuable target for the design of new drugs and
fluorescent probes to study these receptors which may be of value in the research of neurological disorders. A recent study reported on a series of extended chain length Generally it was observed that the an increase in chain length improved NMDA receptor activity which may indicate that deeper immersion into the NMDA receptor is necessary for
stronger interaction of these fluorescent ligands with the putative NMDA binding site. From this series one compound, a dansyl analogue (7, Figure 4 ) was further used as a fluorescent NMDA receptor ligand in a fluorescent displacement competition assay utilizing known
NMDA receptor inhibitors to demonstrate the possible applications of th~s novel fluorescent ligand. This ligand could be used as a direct binding NMDA receptor fluorecent probe that can be quantified and used to directly study these receptors.
An attempt to develop various fluorescent probes to label glutathione (GSH) receptors, led to the serendipitous discovery of a fluorescent ligand that binds to, and antagonises, the NMDA receptor.
[ 51 ] Fluorescent ligand 8 (Figure 4) , a GSH adduct, was shown to displace the competitive NMDA antagonist [3H]-CGP 39653 with a higher affinity than known NMDA receptor inhibitors in rat synaptic membranes.
[ 51 ] In rat cortical experiments 8 reversibly blocked both NMDA-and cysteine-induced depolarization. This study shows that 8 may be a useful selective NMDA antagonist which may be utilised as a fluorescent ligand to study the NMDA receptor. One small-molecule fluorescent ligand described for NO detection was a-diaminonaphthalene also known as DAN, which shows an increase in fluorescent intensity in the presence of NO oxidation products (e.g., N0 2 -, N 2 0 3 ). The disadvantage of this ligand is that it can serve only as an indirect NO sensor.
[ 54 ] DAN also Since neuronal NOS plays a critical role in the production of neuronal NO, it is considered to be a promising neuroprotective therapeutic target.
[ 59 ] The results from inhibition studies showed that four compounds including; indazole-pentacycloundecane (11), coumarin-adamantane (12), cyanoisoindole-adamantane (13) and dansyl-adamantane (14), exhibited IC 50 values of less than 1 J..LM for the NOS enzyme ( Figure 6 ). These compounds could possibly be used as 
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were able to selectively image the subcellular localization of the sigma-2 receptor in the mitochondria, endoplasmic reticulum and in lipid rafts in living cells by CLSM and multi- Figure 13 ) with the first account of selective detection ofNFTs over A~
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plaques. The ligand incorporated a fluorescent BODIPY unit and two lifetime, and emission spectra that may be imaged microscopically or in vivo using new lifetime and spectral fluorescence imaging techniques. NIRF probes that tum on when bound
to AB will improve amyloid detection and may enable quantitative molecular imaging in vivo.
Some of the major hurdles in the development for a succesful NIRF amyloid optical marker are to develop probes that emit above 700 nm, bind amyloid plaques, show good plaque to background contrast and washout kinetics, and cross the blood-brain barrier after intravenous injection. A fluorophore that emits between 700 and 850 nm is optimal because tissue absorption at these wavelengths is the lowest, allowing deeper light penetration. [ 85 -88 ] To date no NIRF amyloid imaging agent has been developed with these optimal properties.
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Conclusion
Fluorescent ligands in combination with fluorescence spectroscopy are becoming a valuable addition to the array of techniques available for scrutinizing ligand-protein interactions in biological systems. In particular, confocal laser scanning microscopy, flow cytometry and multi photon microscopy, allow for noninvasive imaging and quantification of interactions between these small molecule fluorescent ligands and target-proteins in single living cells. As with other imaging technologies, research on small molecule fluorescent ligands in combination with new sophisticated fluorescent techniques should continue to be rapid, and will provide tools to study the processes underlying many biological phenomena in the CNS.
Although numerous fluorescent ligands have been reported so far, none of them are ideal for all applications. Next-generation probes should possess greater sensitivity, selectivity,
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photostability and brightness, more controlled intracellular localization, and superior AD MET properties. Hybridization of fluorescent probes with other imaging agents, such as those for MRI and nuclear imaging, has also emerged and is a promising field. The future challenge lies in the consequent combination of fluorescence detection techniques with procedures to handle, manipulate and analyse molecules, molecular assemblies and biological cells at the micro-and nanometer level. The study of CNS target ligand interactions have a long way to go. Fortunately, technology is advancing rapidly and the combination of new fluorescent ligands, advances in synthetic chemistry methods and new fluorescent imaging techniques will provide us with powerful tools to study CNS biological systems in the future.
